CUE: Here Comes The Data?

CUE: Here Comes The Data?

Cue Biopharma (CUE) is set to present interim Phase 1 data for CUE-101, which could start a rally that ulimately sees shares rise to $150. Here’s why…

CUE: Why Shares Could Be Worth $150 Or More

CUE: Why Shares Could Be Worth $150 Or More

Shares of Cue Biopharma (CUE) are up more than 100% from our entry. But I’m letting this winner ride, as four relevant biotech deals point to another 97% to 637% upside to current prices. Here are all the details…